{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T02:29:29Z","timestamp":1794536969377,"version":"4.9.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:00:00Z","timestamp":1700265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:00:00Z","timestamp":1700265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["21H03070"],"award-info":[{"award-number":["21H03070"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["21H04828"],"award-info":[{"award-number":["21H04828"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007428","name":"Naito Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007428","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Kenzo Suzuki Memorial Foundation"},{"DOI":"10.13039\/501100006724","name":"Japanese Urological Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006724","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22jm0210085, JP22am0401007, and JP22ym0126804 (21-A-22)"],"award-info":[{"award-number":["JP22jm0210085, JP22am0401007, and JP22ym0126804 (21-A-22)"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer Center Research and Development Funds","award":["2020-A-2 and 2023-S-6"],"award-info":[{"award-number":["2020-A-2 and 2023-S-6"]}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Currently, only limited knowledge is available regarding the phenotypic association between fibroblast growth factor receptor 3 (FGFR3) alterations and the tumor microenvironment (TME) in bladder cancer (BLCA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A multi-omics analysis on 389 BLCA and 35 adjacent normal tissues from a cohort of OMPU-NCC Consortium Japan was retrospectively performed by integrating the whole-exome and RNA-sequence dataset and clinicopathological record. A median follow-up duration of all BLCA cohort was 31\u00a0months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p><jats:italic>FGFR3<\/jats:italic> alterations (aFGFR3), including recurrent mutations and fusions, accounted for 44% of non-muscle invasive bladder cancer (NMIBC) and 15% of muscle-invasive bladder cancer (MIBC). Within MIBC, the consensus subtypes LumP was significantly more prevalent in aFGFR3, whereas the Ba\/Sq subtype exhibited similarity between intact FGFR3 (iFGFR3) and aFGFR3 cases. We revealed that basal markers were significantly increased in MIBC\/aFGFR3 compared to MIBC\/iFGFR3. Transcriptome analysis highlighted TIM3 as the most upregulated immune-related gene in iFGFR3, with differential immune cell compositions observed between iFGFR3 and aFGFR3. Using EcoTyper, TME heterogeneity was discerned even within aFGFR cases, suggesting potential variations in the response to checkpoint inhibitors (CPIs). Among 72 patients treated with CPIs, the objective response rate (ORR) was comparable between iFGFR3 and aFGFR3 (20% vs 31%; <jats:italic>p<\/jats:italic>\u2009=\u20090.467). Strikingly, a significantly higher ORR was noted in LumP\/aFGFR3 compared to LumP\/iFGFR3 (50% vs 5%; <jats:italic>p<\/jats:italic>\u2009=\u20090.022). This trend was validated using data from the IMvigor210 trial. Additionally, several immune-related genes, including IDO1, CCL24, IL1RL1, LGALS4, and NCAM (CD56) were upregulated in LumP\/iFGFR3 compared to LumP\/aFGFR3 cases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Differential pathways influenced by aFGFR3 were observed between NMIBC and MIBC, highlighting the upregulation of both luminal and basal markers in MIBC\/aFGFR3. Heterogeneous TME was identified within MIBC\/aFGFR3, leading to differential outcomes for CPIs. Specifically, a favorable ORR in LumP\/aFGFR3 and a poor ORR in LumP\/iFGFR3 were observed. We propose TIM3 as a potential target for iFGFR3 (ORR: 20%) and several immune checkpoint genes, including IDO1 and CCL24, for LumP\/iFGFR3 (ORR: 5%), indicating promising avenues for precision immunotherapy for BLCA.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12943-023-01897-6","type":"journal-article","created":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T11:02:44Z","timestamp":1700305364000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer"],"prefix":"10.1186","volume":"22","author":[{"given":"Kazumasa","family":"Komura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Hirosuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Tokushige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Tsujino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuaki","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuo","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Ura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaya","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Nakamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Maenosono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Ajiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Takai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Tsutsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohito","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Konuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruo","family":"Inamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihito","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihide","family":"Yoshimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhito","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,18]]},"reference":[{"key":"1897_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"1897_CR2","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017;376:1015\u201326.","journal-title":"N Engl J Med"},{"key":"1897_CR3","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1093\/annonc\/mdz127","volume":"30","author":"Y Fradet","year":"2019","unstructured":"Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol. 2019;30:970\u20136.","journal-title":"Ann Oncol"},{"key":"1897_CR4","doi-asserted-by":"crossref","unstructured":"Thomas J, Sonpavde G. Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder Cancer. Cancers (Basel). 2022;14:1795.","DOI":"10.3390\/cancers14071795"},{"key":"1897_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3233\/BLC-200373","volume":"6","author":"MA Knowles","year":"2020","unstructured":"Knowles MA. FGFR3 \u2013 a Central Player in Bladder Cancer Pathogenesis? Bladder Cancer. 2020;6:403\u201323.","journal-title":"Bladder Cancer"},{"key":"1897_CR6","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun A, de Reynies A, Allory Y, Sjodahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. 2020;77:420\u201333.","journal-title":"Eur Urol"},{"key":"1897_CR7","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41416-021-01488-6","volume":"125","author":"TL Rose","year":"2021","unstructured":"Rose TL, Weir WH, Mayhew GM, Shibata Y, Eulitt P, Uronis JM, Zhou M, Nielsen M, Smith AB, Woods M, et al. Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience. Br J Cancer. 2021;125:1251\u201360.","journal-title":"Br J Cancer"},{"key":"1897_CR8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.eururo.2019.06.025","volume":"76","author":"L Wang","year":"2019","unstructured":"Wang L, Gong Y, Saci A, Szabo PM, Martini A, Necchi A, Siefker-Radtke A, Pal S, Plimack ER, Sfakianos JP, et al. Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1\/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. Eur Urol. 2019;76:599\u2013603.","journal-title":"Eur Urol"},{"issue":"540\u2013556","key":"1897_CR9","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017;171(540\u2013556): e525.","journal-title":"Cell"},{"key":"1897_CR10","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","volume":"581","author":"KJ Karczewski","year":"2020","unstructured":"Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alfoldi J, Wang Q, Collins RL, Laricchia KM, Ganna A, Birnbaum DP, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581:434\u201343.","journal-title":"Nature"},{"key":"1897_CR11","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/s41467-020-20146-8","volume":"12","author":"J Takayama","year":"2021","unstructured":"Takayama J, Tadaka S, Yano K, Katsuoka F, Gocho C, Funayama T, Makino S, Okamura Y, Kikuchi A, Sugimoto S, et al. Construction and integration of three de novo Japanese human genome assemblies toward a population-specific reference. Nat Commun. 2021;12:226.","journal-title":"Nat Commun"},{"key":"1897_CR12","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","volume":"381","author":"Y Loriot","year":"2019","unstructured":"Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2019;381:338\u201348.","journal-title":"N Engl J Med"},{"key":"1897_CR13","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","volume":"12","author":"SV Lindskrog","year":"2021","unstructured":"Lindskrog SV, Prip F, Lamy P, Taber A, Groeneveld CS, Birkenkamp-Demtroder K, Jensen JB, Strandgaard T, Nordentoft I, Christensen E, et al. An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nat Commun. 2021;12:2301.","journal-title":"Nat Commun"},{"key":"1897_CR14","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1093\/jnci\/djx243","volume":"110","author":"Q Mo","year":"2018","unstructured":"Mo Q, Nikolos F, Chen F, Tramel Z, Lee YC, Hayashi K, Xiao J, Shen J, Chan KS. Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas. J Natl Cancer Inst. 2018;110:448\u201359.","journal-title":"J Natl Cancer Inst"},{"key":"1897_CR15","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, Khodadoust MS, Esfahani MS, Luca BA, Steiner D, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37:773\u201382.","journal-title":"Nat Biotechnol"},{"key":"1897_CR16","doi-asserted-by":"publisher","first-page":"5482","DOI":"10.1016\/j.cell.2021.09.014","volume":"184","author":"BA Luca","year":"2021","unstructured":"Luca BA, Steen CB, Matusiak M, Azizi A, Varma S, Zhu C, Przybyl J, Espin-Perez A, Diehn M, Alizadeh AA, et al. Atlas of clinically distinct cell states and ecosystems across human solid tumors. Cell. 2021;184:5482-5496 e5428.","journal-title":"Cell"},{"key":"1897_CR17","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O\u2019Donnell PH, Balmanoukian A, Loriot Y, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909\u201320.","journal-title":"Lancet"},{"key":"1897_CR18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1158\/2326-6066.CIR-15-0274","volume":"4","author":"RF Sweis","year":"2016","unstructured":"Sweis RF, Spranger S, Bao R, Paner GP, Stadler WM, Steinberg G, Gajewski TF. Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunol Res. 2016;4:563\u20138.","journal-title":"Cancer Immunol Res"},{"key":"1897_CR19","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","volume":"18","author":"P Sharma","year":"2017","unstructured":"Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18:312\u201322.","journal-title":"Lancet Oncol"},{"key":"1897_CR20","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1038\/s41467-018-05992-x","volume":"9","author":"L Wang","year":"2018","unstructured":"Wang L, Saci A, Szabo PM, Chasalow SD, Castillo-Martin M, Domingo-Domenech J, Siefker-Radtke A, Sharma P, Sfakianos JP, Gong Y, et al. EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nat Commun. 2018;9:3503.","journal-title":"Nat Commun"},{"key":"1897_CR21","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1200\/JCO.2022.40.16_suppl.2504","volume":"40","author":"GS Falchook","year":"2022","unstructured":"Falchook GS, Ribas A, Davar D, Eroglu Z, Wang JS, Luke JJ, Hamilton EP, Di Pace B, Wang T, Ghosh S, et al. Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER). J Clin Oncol. 2022;40:2504\u20132504.","journal-title":"J Clin Oncol"},{"key":"1897_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13045-021-01080-8","volume":"14","author":"K Tang","year":"2021","unstructured":"Tang K, Wu YH, Song Y, Yu B. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy. J Hematol Oncol. 2021;14:68.","journal-title":"J Hematol Oncol"},{"key":"1897_CR23","doi-asserted-by":"publisher","first-page":"1777625","DOI":"10.1080\/2162402X.2020.1777625","volume":"9","author":"J Le Naour","year":"2020","unstructured":"Le Naour J, Galluzzi L, Zitvogel L, Kroemer G, Vacchelli E. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology. 2020;9:1777625.","journal-title":"Oncoimmunology"},{"key":"1897_CR24","doi-asserted-by":"publisher","unstructured":"Brian SW, Aur\u00e9lien de R, Aaron MN, Joshua JW, Andrew L, Florent P, Alberto V, Yating L, Haojun L, Xu X, et al. Community assessment of methods to deconvolve cellular composition from bulk gene expression. bioRxiv. 2022.06.03.494221. https:\/\/doi.org\/10.1101\/2022.06.03.494221.","DOI":"10.1101\/2022.06.03.494221"},{"key":"1897_CR25","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nbt.3758","volume":"35","author":"N Yachie","year":"2017","unstructured":"Yachie N, Natsume T. Robotic crowd biology with Maholo LabDroids. Nat Biotechnol. 2017;35:310\u20132.","journal-title":"Nat Biotechnol"},{"key":"1897_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38: e164.","journal-title":"Nucleic Acids Res"},{"key":"1897_CR27","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453\u20137.","journal-title":"Nat Methods"},{"key":"1897_CR28","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","volume":"18","author":"AV Balar","year":"2017","unstructured":"Balar AV, Castellano D, O\u2019Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18:1483\u201392.","journal-title":"Lancet Oncol"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-023-01897-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-023-01897-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-023-01897-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T05:30:24Z","timestamp":1700371824000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-023-01897-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,18]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1897"],"URL":"https:\/\/doi.org\/10.1186\/s12943-023-01897-6","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,18]]},"assertion":[{"value":"31 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been performed based on the principles of the World Medical Association Declaration of Helsinki. The study designs were approved by the institutional review board at Osaka Medical and Pharmaceutical University [OMPU-IRB approval number: No. 2305-11 (approval date: Nov 24th, 2017), No. 2344-10 (approval date: Nov 24th, 2017), No. 2523-3 (approval date: Jul 27th, 2018), No. 2808-2 (approval date: Jan 10th, 2020), No. 2571-6 (approval date: Nov 7th, 2018)]) and National Cancer Center Japan (NCC-IRB approval number: 2020\u2013486, Date of approval: February 9th, 2021). All patients provided written informed consent prior to the analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors, by giving their consent to participate, have given their consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"185"}}